Novo Nordisk A/S (NYSE:NVO) Shares Sold by Jennison Associates LLC

Jennison Associates LLC trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 1.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 19,944,809 shares of the company’s stock after selling 251,148 shares during the period. Novo Nordisk A/S comprises 1.0% of Jennison Associates LLC’s investment portfolio, making the stock its 23rd biggest holding. Jennison Associates LLC owned approximately 0.44% of Novo Nordisk A/S worth $1,715,652,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the stock. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S during the third quarter worth $28,000. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at about $42,000. Albion Financial Group UT increased its stake in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares during the period. Sound Income Strategies LLC boosted its stake in shares of Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after purchasing an additional 243 shares during the period. Finally, Carolina Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the third quarter valued at approximately $48,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $84.36 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a 50-day simple moving average of $93.56 and a 200-day simple moving average of $112.87. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The company has a market capitalization of $378.56 billion, a price-to-earnings ratio of 27.30, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.